Notably, BMAL1 is strongly enriched in post-enzalutamide-treated PCa tissues and is essential for sustaining the growth of enzalutamide-resistant PCa cells, highlighting its potential as a therapeutic target in androgen-independent PCa. The gene discussed is BMAL1; the disease is posterior cortical atrophy.